Update on Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the elderly, affecting 1 in 20 adults over the age of 70 years. Stroke is a major yet highly preventable complication of AF, and the strokes related to AF often are disabling and fatal. Warfarin is the treatment of choice in high-risk patients with AF, and its superior efficacy over aspirin for preventing stroke in these patients is widely recognized. However, several eligible patients with AF are not being treated with warfarin or are being treated inadequately, largely because of concerns regarding the attendant strict monitoring, drug interactions, and risk of major bleeding. As such, alternative antithrombotic therapies that can rival or exceed the efficacy of warfarin, yet compare favorably with its administration and side effect profile, are being sought. One such strategy, the use of a combination antiplatelet regimen, for stroke prevention in high-risk patients with nonvalvular AF was investigated recently in two clinical trials. This article reviews the role of combination antiplatelet regimens in stroke prevention for patients with AF. Other therapies discussed include oral anticoagulation, single antiplatelet therapies, oral anticoagulation plus antiplatelet treatment, direct thrombin inhibitors, and factor Xa inhibitors.
- Lafuente-Lafuente C, Mahe I, Extramiana F: Management of atrial fibrillation. BMJ 2009, 339:b5216. CrossRef
- Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983–988.
- Sacco RL, Adams R, Albers G, et al.: American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006, 37:577–617. CrossRef
- van Walraven C, Hart RG, Singer DE, et al.: Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002, 288:2441–2448. CrossRef
- Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999, 131:492–501.
- Halbmayer WM, Haushofer A, Schön R, Fischer M: The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994, 5:51–57. CrossRef
- Hylek EM, Skates SJ, Sheehan MA, et al.: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996, 335:540–546. CrossRef
- Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993, 342:1255–1262
- Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996, 348:633–638
- Akins PT, Feldman HA, Zoble RG, et al.: Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Stroke 2007, 38:874–880. CrossRef
- Perez-Gomez F, Alegria E, Berjon J, et al.: Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004, 44(8):1557–1566. CrossRef
- Dale J, Myhre E, Storstein O, et al.: Prevention of arterial thromboembolism with acetylsalicylic acid. A controlled clinical study in patients with aortic ball valves. Am Heart J 1977, 94:101–111. CrossRef
- ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, et al.: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006, 367:1903–1912. CrossRef
- ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, et al.: Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009, 360:2066–2078. CrossRef
- Connolly SJ, Ezekowitz MD, Yusuf S, et al.: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361(12):1139–1151. CrossRef
- Amadeus Investigators, Bousser MG, Bouthier J, Büller HR, Bousser MG, Bouthier J, Büller HR, et al.: Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008, 371(9609):315–321. CrossRef
- Singer DE, Albers GW, Dalen JE, et al.: American College of Chest Physicians: Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:546S–592S. CrossRef
- Micromedex. Available at http://www.Thomsonhc.Com/home/dispatch. Accessed February 2010.
- Epocrates. Available at http://www.Epocrates.com. Accessed February 2010.
- Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146(12):857–867.
- Update on Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Current Treatment Options in Cardiovascular Medicine
Volume 12, Issue 3 , pp 250-260
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links